A Phase I/II Study of Llme Treated Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematological Malignancies.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Stem cell therapies
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 29 Nov 2016 Biomarkers information updated
- 10 Sep 2010 New trial record